Entero Therapeutics Inc.
13F holders, Q4 2024 (December 31)9holders −1
1new positions
3sold out
$0.62avg. 13F price*
At the end of Q4 2024, 9 institutions reported holding Entero Therapeutics Inc. in their 13F filings, down 1 from Q3 2024. 1 opened new positions and 3 sold out. The largest holders were Ground Swell Capital, LLC ($16K), Geode Capital Management, LLC ($12K) and Two Sigma Securities, LLC ($6K).
- Company
- Entero Therapeutics Inc.
- CUSIP
- 33749P408
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $16K |
| Exits | 3 | $14K |
All 13F filers, Q3 2024 → Q4 2024: 37,571 shares bought and 61,252 shares sold, net −23,681 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Ground Swell Capital, LLC | 0.04% | New | 26,231 | $16K |
| Geode Capital Management, LLC | 0.00% | Add +23.7% | 19,857 | $12K |
| Two Sigma Securities, LLC | 0.00% | Reduce -62.1% | 10,073 | $6K |
| UBS Group AG | 0.00% | Add +752500.0% | 7,526 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -32.3% | 5,064 | $3K |
| SBI Securities Co., Ltd. | 0.00% | — | 2,507 | $2K |
| FMR LLC | 0.00% | Reduce -5.2% | 915 | $569 |
| Bank of America Corp. | 0.00% | Add +50.0% | 39 | $24 |
| US Bancorp \de | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is ENTERO THERAPEUTICS INC's weight in each manager's 13F, not the share of Entero Therapeutics Inc. the manager owns.